Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$425.21
-1.8%		$478.03
$353.54
▼
$615.00
$10.06B-0.98572,645 shs391,328 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.58
-3.0%		$29.54
$23.82
▼
$43.10
$3.63B0.794.29 million shs2.19 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.10%+8.14%-7.31%-14.65%-20.03%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.77%+1.68%+0.35%-13.66%-29.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$425.21
-1.8%		$478.03
$353.54
▼
$615.00
$10.06B-0.98572,645 shs391,328 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.58
-3.0%		$29.54
$23.82
▼
$43.10
$3.63B0.794.29 million shs2.19 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.10%+8.14%-7.31%-14.65%-20.03%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.77%+1.68%+0.35%-13.66%-29.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.76
Moderate Buy$706.8766.24% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.79
Moderate Buy$93.36238.52% Upside

Current Analyst Ratings Breakdown

Latest VKTX and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
11/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageStrong-Buy
11/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$612.00 ➝ $633.00
11/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$709.00 ➝ $743.00
11/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$725.00 ➝ $760.00
10/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$106.00 ➝ $118.00
10/29/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral$34.00
10/20/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$114.00 ➝ $106.00
10/15/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/14/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$94.00
(Data available from 11/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M10.31N/AN/A$26.99 per share15.75
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$5.98N/A58.25N/A-10.89%-27.08%-12.04%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$5.40N/AN/AN/AN/A-117.35%-88.87%N/A

Latest VKTX and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$1.09$1.83+$2.92$1.83$404.17 million$431.27 million
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.06-$1.55-$0.49-$1.55N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.54
3.05
2.78
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.43
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.23 million19.14 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
74127.52 million120.76 millionOptionable

Recent News About These Companies

Viking Therapeutics stock trades at EUR 25.68 on Thursday
November 12 at 11:03 AM  |  ad-hoc-news.deA
Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?
November 12 at 6:02 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-priced-perfection-043400765.html
Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?
November 12 at 6:02 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-vktx-heads-two-091058168.html
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
November 11 at 5:34 PM  |  fool.comhttps://www.fool.com/investing/2026/11/11/eli-lilly-just-raised-its-2026-sales-forecast-to-a/
Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
November 11 at 5:00 PM  |  fxempire.comF
Viking Therapeutics stock trades at 26.00 euros Tuesday
November 10 at 10:01 AM  |  ad-hoc-news.deA
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
November 9 at 9:55 AM  |  zacks.comhttps://www.zacks.com/stock/news/3026175/novo-up-4-in-a-month-how-should-investors-approach-the-stock-now?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3026175
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
November 9 at 9:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-4-month-investors-approach-125100467.html
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
November 9 at 9:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-two-poster-120500193.html
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
November 9 at 7:05 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-announces-two-poster-presentations-at-obesityweek-2026-302932884.html
Can You Justify Buying Corcept Stock Today?
November 8, 2026  |  trefis.comT
Here's the 1 Stock I'd Most Want to Buy If the Market Crashes
November 5, 2026  |  fool.comhttps://www.fool.com/investing/2026/11/05/the-1-stock-id-most-want-to-buy-if-the-market/
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
November 4, 2026  |  fool.comhttps://www.fool.com/investing/2026/11/04/viking-therapeutics-trades-xx-below-its-own-35-off/
Viking Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-participate-upcoming-investor-213000179.html
Viking Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302928444.html
Viking Therapeutics (NASDAQ:VKTX) Stock Price Target Raised at Canaccord Genuity Group
November 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-viking-therapeutics-nasdaq-vktx-stock-price-target-raised-at-canaccord-genuity-group-2026-11-02/
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
November 2, 2026  |  fool.comhttps://www.fool.com/investing/2026/11/02/ubs-just-initiated-coverage-of-viking-therapeutics/
HC Wainwright Issues Pessimistic Estimate for VKTX Earnings
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31172612
HC Wainwright Has Negative Estimate for VKTX FY2026 Earnings
November 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-negative-estimate-for-vktx-fy2026-earnings-2026-11-02/
Viking Therapeutics Bets Big on VK2735 in Earnings Call
October 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/8565720/viking-therapeutics-bets-big-on-vk2735-in-earnings-call/
Viking Therapeutics: A Strong Injection, A Scaled-Back Pill
October 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4960571-viking-therapeutics-a-strong-injection-a-scaled-back-pill

New MarketBeat Followers Over Time

Media Sentiment Over Time

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$425.21 -7.82 (-1.81%)
Closing price 04:00 PM Eastern
Extended Trading
$425.00 -0.21 (-0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$27.58 -0.86 (-3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$27.72 +0.14 (+0.51%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas